Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Proton Pump Inhibitors Market From 2025 to 2029?

The market size for proton pump inhibitors has experienced consistent expansion over the past few years. The sector is set to expand from $3.4 billion in 2024 to $3.51 billion in 2025, with a compound annual growth rate (CAGR) of 3.2%. This growth during the historic period can be credited to the common occurrence of gastroesophageal reflux disease (GERD), frequency of peptic ulcer disease, growing elderly population, modifications in lifestyle and diet, as well as enhanced awareness and diagnosis.

In the coming years, we are likely to see a considerable expansion in the proton pump inhibitors market. It’s projected to increase to “$4.29 billion in 2029 with a compound annual growth rate (CAGR) of 5.1%. This hike during the forecast period may be due to factors such as the embrace of emerging markets, an escalation in the prevalence of helicobacter pylori infections, efforts to educate patients, strategic marketing initiatives, and promotional strategies. Major trends to look out for during the forecast period comprise integration with digital health solutions, expansion of the worldwide market, emphasis on educating about gastrointestinal health, regulatory modifications, safety precautions, and factors concerning environmental impact.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10791&type=smp

What Elements Are Contributing To Growth In The Proton Pump Inhibitors Market?

The rising incidence of gastrointestinal issues is anticipated to fuel the expansion of the proton pump inhibitors market. Gastrointestinal issues encompass a variety of diseases including nausea, vomiting, food poisoning, and diarrhea, which affect the biological function of the gastrointestinal (GI) tract. Commonly prescribed medications for heartburn and acid-related disorders are proton pump inhibitors (PPIs); they limit the volume of stomach acid produced by the stomach lining’s glands. The increasing incidence of gastrointestinal problems promotes the development of proton pump inhibitors. For example, Cancer Australia, an Australian cancer control organization aiming to assist cancer patients and raise disease awareness, projected 2,572 new cases of stomach cancer in Australia in September 2022 (1,661 male and 911 female cases). Additionally, as per a survey conducted by the American Gastroenterological Association, a US-based medical association comprising more than 16,000 physicians and scientists, over 40% of Americans ended daily activities in the past year due to severe gastrointestinal symptoms, such as exercising (19%), completing tasks (17%), and socializing (16%). Consequently, the escalating incidence of gastrointestinal issues is likely to drive the growth of the proton pump inhibitors market.

The proton pump inhibitors market covered in this report is segmented –

1) By Type: Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, Dexlansoprazole, Other Types

2) By Disease Allocation: Ulcers, Gastroesophageal Reflux Disease, Other Disease Indications

3) By Application: Hospitals, Clinic, Other Applications

Subsegments:

1) By Pantoprazole: Tablet Formulations, Injectable Formulations

2) By Omeprazole: Over-The-Counter (OTC) Omeprazole, Prescription Omeprazole

3) By Lansoprazole: Fast-Acting Lansoprazole, Delayed-Release Lansoprazole

4) By Esomeprazole: Oral Esomeprazole, Intravenous Esomeprazole

5) By Rabeprazole: Rabeprazole Tablets, Extended-Release Rabeprazole

6) By Dexlansoprazole: Standard Dexlansoprazole, Modified-Release Dexlansoprazole

7) By Other Types: Combination Formulations, Lesser-Known PPIs

What Notable Trends Are Shaping The Direction Of The Proton Pump Inhibitors Market?

Leading firms in the proton pump inhibitors market are concentrating on enhancing technology, such as Rabeprazole + Levosulpiride SR Capsules to elevate the remedy for acid-related complications. The Rabeprazole + Levosulpiride SR Capsules, an innovative drug, have been developed to tackle gastrointestinal issues including gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS). For instance, in June 2024, Akums Drugs & Pharmaceuticals, a pharmaceutical firm based in India, introduced Rabeprazole + Levosulpiride SR Capsules. These Rabeprazole + Levosulpiride SR (Sustained Release) Capsules, a combined medication, is used to manage acid-related gastrointestinal problems, such as gastroesophageal reflux disease (GERD), functional dyspepsia, and other conditions related to excessive stomach acid and disrupted digestive movement.

Who Are The Key Contributors To Growth In The Proton Pump Inhibitors Market?

Major companies operating in the proton pump inhibitors market include AstraZeneca plc, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company, Santarus Inc., Janssen Pharmaceuticals, GlaxoSmithKline plc, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Sanofi S.A., Johnson & Johnson, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Cipla Limited, Hetero Drugs Limited, Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Limited, Panacea Biotec Ltd., Strides Pharma Science Limited, Wockhardt Ltd.

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Which Region Is Projected To Lead The Proton Pump Inhibitors Market By 2025?

North America was the largest region in the proton pump inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global proton pump inhibitors market size during the forecast period. The regions covered in the proton pump inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10791&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model